Mounjaro is Eli Lilly's brand of tirzepatide for type 2 diabetes, the first dual GIP/GLP-1 receptor agonist. Since August 27, 2026 it is also FDA-approved to reduce major CV events in adults with T2D at high CV risk.
At a glance
- Generic name: tirzepatide
- Manufacturer: Eli Lilly
- List price: not re-checked in October 2026; see the manufacturer's pricing page
- Cash-pay program: Lilly savings cards for commercial
FDA-approved indications
- Type 2 diabetes (2022)
- Reduction of major adverse CV events in adults with T2D at high CV risk (August 27, 2026; basis: SURPASS-CVOT, non-inferior to Trulicity, HR 0.92, 95.3% CI 0.83 to 1.01)
Standard dosing
- Start: 2.5 mg/wk × 4 wk
- Titration: 5 → 7.5 → 10 → 12.5 → 15 mg
- Maintenance: 5–15 mg weekly